Advanced search

Authors whose works are in public domain in at least one jurisdiction

List of works by Oliver Ottmann

1-50 of 218 results

View this query on the Wikidata Query Service
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

scientific article published in February 2002
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

scientific article (publication date: 15 June 2006)
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

scientific article published in May 2002
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival

scientific article published on 16 May 2011
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

scientific article published in March 2002
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

scientific article
Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.

scholarly article
Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes

scientific article published on 2 March 2012
Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis

scientific article published on 21 December 2006
Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study

scientific article
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results

scientific article published on 22 November 2010
Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes

scientific article
Treatment of patients with advanced cancer with the natural killer cell line NK-92.

scientific article published on October 2013
Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial

scientific article published on 29 July 2013
Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL)

scientific article published on 25 April 2006
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

scientific article
Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor

scientific article
Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)

article
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development

scientific article published in October 2005
Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

scientific article published on 7 April 2005
Demonstration of the Th1 to Th2 cytokine shift during the course of HIV-1 infection using cytoplasmic cytokine detection on single cell level by flow cytometry

article
Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation

scientific article published in March 2002
Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia

scientific article published on 5 December 2012
IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis

scientific article
Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells

scientific article
A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia

scientific article published on 03 July 2003
Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study

scientific article published on February 2002
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study.

scientific article
Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies.

scientific article
Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia

scientific article published on 28 December 2009
Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588.

scientific article
IL-18 activates STAT3 in the natural killer cell line 92, augments cytotoxic activity, and mediates IFN-gamma production by the stress kinase p38 and by the extracellular regulated kinases p44erk-1 and p42erk-21

scientific article published in August 2000
Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib

scientific article published on 18 November 2009
Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma.

scientific article published on 5 August 2009
Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia.

scientific article
Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia

scientific article published on 27 March 2003
Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL

scientific article published on 27 April 2016
The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate

scientific article published on 22 May 2003
Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia

scientific article published in September 2003
UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia

scientific article published on 05 July 2007
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C.

scientific article published in December 2003
Impact of leukapheresis on early death rate in adult acute myeloid leukemia presenting with hyperleukocytosis

scientific article published on 01 October 2007
PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia

scientific article
Gamma-catenin contributes to leukemogenesis induced by AML-associated translocation products by increasing the self-renewal of very primitive progenitor cells.

scientific article
Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate.

scientific article published in October 2003
Mechanisms of Bcr-Abl-mediated NF-kappaB/Rel activation

scientific article
Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

scientific article published in January 2009
SETBP1 mutation analysis in 944 patients with MDS and AML.

scientific article published on 7 May 2013
Acute lymphoblastic leukemia

scientific article published on 01 January 2002
Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia

scientific article published on March 2005

Paulina is supported by:

About Paulina

Help